Vigil Neuroscience announced on 21st May that they will be acquired by Sanofi who have decided they will not be purchasing Iluzanebart (VGL101), Vigil’s monoclonal antibody being studied in a Phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Yesterday, Vigil announced an update on the IGNITE Phase 2 trial with Iluzanebart. After reviewing final data analysis, they determined there were no beneficial effects on biomarkers or clinical endpoints observed in CSF1R-ALSP patients treated with Iluzanebart. Unfortunately, they have decided that the Phase 2 IGNITE long-term extension study, and the ILLUMINATE Natural History Study will be discontinued.
The Sisters’ Hope Foundation externally-led patient focused drug development (EL-PFDD) session will be held virtually on Friday 20th June 2025 at 6pm British Summer Time. They are calling on the ALSP community to come together to shine a light on the devastation caused by ALSP and the urgent need for a treatment and cure.
